Equity |
On May 26, 2023, the Company’s Board of Directors approved a reverse stock split of the common stock, par value $0.01 per share, of the Company at a ratio of one-for-25 shares and a reduction in the total number of authorized shares of common stock of the Company from 350,000,000 shares to 28,000,000 shares, each effective on June 9, 2023. Accordingly, all common stock, equity award, warrant, and per share amounts have been adjusted to reflect the reverse stock split for all prior periods presented. For additional information related to the reverse stock split, see Note 1, Basis of Preparation of Financial Statements and Nature of Operations. On May 9, 2024, the Company’s shareholders approved an increase to the Company’s authorized shares from 28,000,000 shares to 100,000,000 shares. To effect the increase in authorized shares, the Company filed an amendment to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on May 13, 2024. June 2023 Offering and Private Placement Transaction On June 26, 2023, the Company entered into a Securities Purchase Agreement with certain institutional investors providing for the issuance and sale by the Company in a registered direct offering (the “June 2023 Offering”) of an aggregate of 790,000 shares of the Company’s common stock at a purchase price of $1.45 per share and pre-funded warrants exercisable for up to 637,587 shares of the Company’s common stock (the “June 2023 Pre-Funded Warrants”) at a purchase price of $1.4499 per June 2023 Pre-Funded Warrant. In a concurrent private placement (the “June 2023 Private Placement” and, together with the June 2023 Offering, the “June 2023 Transactions”), the Company agreed to issue warrants to purchase up to 1,427,587 shares of the Company’s common stock at an exercise price of $1.90 (the “June 2023 Warrants”). The aggregate net proceeds from the June 2023 Transactions were approximately $1.9 million. See – Common Stock Warrants for additional information about the June 2023 Pre-Funded Warrants and the June 2023 Warrants. November 2023 Public Offering On November 6, 2023, the Company entered into a Securities Purchase Agreement with certain institutional investors providing for the issuance and sale by the Company in a public offering (the “November 2023 Offering”) of (i) an aggregate of 4,712,488 shares of the Company’s common stock, par value $0.01 per share (the “Initial Shares”); (ii) Series A common warrants (the “November 2023 Series A Warrants”) to purchase 6,000,000 Common Shares; (iii) Series B warrants (the “November 2023 Series B Warrants”) to purchase 3,000,000 Common Shares; (iv) pre-funded warrants (the “November 2023 Pre-Funded Warrants”) to purchase 1,287,512 shares of the Company’s common stock for aggregate net proceeds of approximately $3.8 million. During the quarter ended March 31, 2024, the 488,572 November 2023 Pre-Funded Warrants were exercised for net proceeds of $48.86; 798,940 of these warrants were exercised in the fourth quarter 2023 for net proceeds of $70.89. See – Common Stock Warrants for additional information about the November 2023 Series A Warrants, the November 2023 Series B Warrants, and the November 2023 Pre-Funded Warrants. At-the-Market Offering Agreement During the nine months ended September 30, 2024, the Company did not sell any shares of common stock under the At-the-Market-Offering-Agreement Program (“ATM Program”). The ATM Program has not been in effect since the related Registration Statement on Form S-3 expired on October 1, 2023. During the nine months ended September 30, 2023, the Company sold an aggregate of 308,930 shares of common stock under the ATM Program at an average price of $6.19 per share of common stock for net proceeds, after commissions and fees, of approximately $1,839,000. There were no deferred ATM Program costs amortized during the nine months ended September 30, 2024. Approximately $45,000 of deferred ATM Program costs were amortized during the nine months ended September 30, 2023. At September 30, 2024 and December 31, 2023, there was no remaining balance of deferred ATM Program costs, recorded in Prepaid expenses and other assets on the interim Condensed Consolidated Balance Sheets. Equity Incentive Plans Restricted Stock Grants The following table summarizes the status and activity of the Company’s restricted stock grants at September 30, 2024 and 2023, and the changes during the nine months then ended: | | | | | | | | | | | | | Nine Months Ended September 30, | | | 2024 | | 2023 | | | | | Weighted | | | | Weighted | | | | | Average | | | | Average | | | | | Grant Date | | | | Grant Date | | | Number of | | Fair Value | | Number of | | Fair Value | Restricted Stock Grants | | Shares | | Per Share | | Shares | | Per Share | Outstanding at beginning of period | | 5,800 | | $ | 8.89 | | 19,800 | | $ | 10.95 | Granted during the period | | — | | | — | | — | | | — | Restrictions lifted during the period | | (3,936) | | | 9.75 | | (12,933) | | | 11.97 | Forfeited during the period | | (534) | | | 9.75 | | — | | | — | Outstanding at end of period | | 1,330 | | $ | 6.00 | | 6,867 | | $ | 9.02 |
Restricted Stock Units The following table summarizes the status and activity of the Company’s restricted stock units at September 30, 2024 and 2023, and the changes during the nine months then ended: | | | | | | | | | | | | | Nine Months Ended September 30, | | | 2024 | | 2023 | | | | | Weighted | | | | Weighted | | | | | Average | | | | Average | | | | | Grant Date | | | | Grant Date | | | Number of | | Fair Value | | Number of | | Fair Value | Restricted Stock Units | | Shares | | Per Share | | Shares | | Per Share | Outstanding at beginning of period | | 272,409 | | $ | 13.09 | | 232,409 | | $ | 15.06 | Granted during the period | | 1,200,000 | | | 0.41 | | 40,000 | | | 1.62 | Shares issued during the period | | (373,493) | | | 3.08 | | — | | | — | Forfeited during the period | | (28,837) | | | 19.47 | | — | | | — | Outstanding at end of period | | 1,070,079 | | $ | 2.36 | | 272,409 | | $ | 13.09 |
Key Employee Long-Term Incentive Plan There were zero and 168,000 Key Employee Long Term Incentive Plan (“KELTIP”) Units outstanding at September 30, 2024 and December 31, 2023, respectively. Under the 2023 Equity Incentive Plan (“the 2023 Plan”), the Company discontinued the KELTIP and will no longer issue KELTIP Units. Stock-Based Compensation Stock-based compensation expense for the periods presented is as follows: | | | | | | | | | | | | | Three Months Ended September 30, | | Nine Months Ended September 30, | | 2024 | | 2023 | | 2024 | | 2023 | | | (in thousands) | | (in thousands) | Restricted stock grants | $ | 1 | | $ | 20 | | $ | 19 | | $ | 75 | Restricted stock units | | 79 | | | 58 | | | 315 | | | 270 | KELTIP units | | — | | | 14 | | | 3 | | | (21) | | $ | 80 | | $ | 92 | | $ | 337 | | $ | 324 |
Common Stock Warrants The following table summarizes the activity of the Company’s common stock warrants for the nine months ended September 30, 2024 and September 30, 2023. | | | | | | | | | | | | | Nine Months Ended September 30, | | | 2024 | | 2023 | | | | | Weighted | | | | Weighted | | | Number of | | Average | | Number of | | Average | | | Underlying | | Exercise Price | | Underlying | | Exercise Price | Common Stock Warrants | | Shares | | Per Share | | Shares | | Share | Outstanding at beginning of period | | 11,308,314 | | $ | 1.09 | | 392,155 | | $ | 8.58 | Granted during period | | — | | | — | | 2,065,174 | | | 1.31 | Exercised during period | | | | | | | | | | | 2023 Pre-Funded Warrants | | (488,572) | | | 0.0001 | | (637,587) | | | 0.0001 | Expired during the period | | — | | | — | | — | | | | Outstanding at end of period | | 10,819,742 | | $ | 1.14 | | 1,819,742 | | $ | 3.19 |
The common stock warrants relate to prior registered offerings and private placements of the Company’s stock. Common stock warrants outstanding as of September 30, 2024 are as follows: | | | | | | | | | | Number of | | Exercise | | | Common Stock Warrants | | Warrants | | Price | | Expiration Date | July 2019 Series A Warrants | | 338,155 | | $ | 8.75 | | January 17, 2025 | April 2020 Series A Warrants | | 44,000 | | $ | 0.70 | | October 22, 2025 | April 2020 Series B Warrants | | 10,000 | | $ | 6.50 | | October 22, 2025 | June 2023 Warrants | | 1,427,587 | | $ | 1.90 | | December 26, 2028 | November 2023 Series A Warrants | | 6,000,000 | | $ | 0.70 | | November 6, 2028 | November 2023 Series B Warrants | | 3,000,000 | | $ | 0.70 | | May 6, 2025 | | | 10,819,742 | | | | | |
All outstanding common stock warrants are recorded in equity at September 30, 2024 and December 31, 2023, following the guidance established by ASC Topic 815-40. The Company’s common stock warrants allow for potential settlement in cash if certain extraordinary events are effected by the Company, including a 50% or greater change of control in the Company’s common stock. Since those events have been deemed to be within the Company’s control, the Company continues to apply equity treatment for these common stock warrants.
|